Login

Urologic Oncology

The future of bladder-sparing therapy is bright

Tissue-based biomarkers steering clinical decisions in patients with urothelial cancer

Are standard repeat biopsies during active surveillance for prostate cancer still necessary?

Disconnect between clinical trials and real-world oncology patients

Preoperative risk stratification of high-risk prostate cancer patients

When partial nephrectomy is unsuccessful (1)

Intravesical cytosine arabinoside + Mitomycin C for bladder cancer – is it beneficial?

Save the orchid

Defining adjuvant, consolidative, and salvage treatment after RP

Men’s Health in Primary Care

Prostate Cancer – Diagnosis and Clinical Management

Urological Cancer Management
Prev
Next
× UAT site